In the published manuscript for which this data set was created, we
provide detailed protocols for the measurement of the immunoreactivity of
radiolabeled antibodies. To provide some context, full-length antibodies
and smaller antibody fragments have been viewed as promising vectors for
the delivery of radionuclides to tumor tissues for decades. The creation
of radioimmunoconjugates is predicated on the direct attachment of a
radionuclide (i.e. a radiohalogen) or the initial bioconjugation of a
chelator that can then be used to coordinate a radiometal. These two
approaches have traditionally relied upon random reactions with residues
within the immunoglobulin; however, stochastic modification strategies
inevitably risk the integrity of the biomolecule itself and, as a result,
can provide radioimmunoconjugates with subpar in vivo behavior. The
initial evaluation of any novel radiolabeled antibody or antibody fragment
should therefore involve the determination of the immunoconjugate's
ability to bind its cognate antigen. These spreadsheets are companions to
a manuscript in which we provide detailed protocols for three assays that
can be used to determine the immunoreactivity of a radioimmunoconjugate:
(1) a cell-based linear extrapolation assay; (2) a cell-based antigen
saturation assay; and (3) a resin- or bead-based assay. These are
spreadsheets that accompany our guide to measuring the immunoreactivity of
radioimmunoconjugates.